|
US4522811A
(en)
|
1982-07-08 |
1985-06-11 |
Syntex (U.S.A.) Inc. |
Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
|
|
US4828991A
(en)
|
1984-01-31 |
1989-05-09 |
Akzo N.V. |
Tumor specific monoclonal antibodies
|
|
US5369108A
(en)
|
1991-10-04 |
1994-11-29 |
Sloan-Kettering Institute For Cancer Research |
Potent inducers of terminal differentiation and methods of use thereof
|
|
US5502187A
(en)
|
1992-04-03 |
1996-03-26 |
The Upjohn Company |
Pharmaceutically active bicyclic-heterocyclic amines
|
|
US5497763A
(en)
|
1993-05-21 |
1996-03-12 |
Aradigm Corporation |
Disposable package for intrapulmonary delivery of aerosolized formulations
|
|
US5508269A
(en)
|
1994-10-19 |
1996-04-16 |
Pathogenesis Corporation |
Aminoglycoside formulation for aerosolization
|
|
US6777217B1
(en)
|
1996-03-26 |
2004-08-17 |
President And Fellows Of Harvard College |
Histone deacetylases, and uses related thereto
|
|
US6083922A
(en)
|
1996-04-02 |
2000-07-04 |
Pathogenesis, Corp. |
Method and a tobramycin aerosol formulation for treatment prevention and containment of tuberculosis
|
|
US5767068A
(en)
|
1997-02-13 |
1998-06-16 |
Pathogenesis Corporation |
Pure biologically active colistin, its components and a colistin formulation for treatment of pulmonary infections
|
|
EP1277738B1
(en)
|
2000-04-27 |
2011-03-30 |
Astellas Pharma Inc. |
Condensed heteroaryl derivatives
|
|
US6608053B2
(en)
|
2000-04-27 |
2003-08-19 |
Yamanouchi Pharmaceutical Co., Ltd. |
Fused heteroaryl derivatives
|
|
HRP20040801A2
(en)
|
2002-03-13 |
2005-04-30 |
Janssen Pharmaceutica N.V. |
Sulfonylamino derivatives as novel inhibitors of histone deacetylase
|
|
EP1485348B1
(en)
|
2002-03-13 |
2008-06-11 |
Janssen Pharmaceutica N.V. |
Carbonylamino-derivatives as novel inhibitors of histone deacetylase
|
|
US7205304B2
(en)
|
2002-03-13 |
2007-04-17 |
Janssen Pharmaceutica N.V. |
Sulfonyl-Derivatives as novel inhibitors of histone deacetylase
|
|
ATE425152T1
(de)
|
2002-03-13 |
2009-03-15 |
Janssen Pharmaceutica Nv |
Aminocarbonylderivate als histone-deacetylase- inhibitoren
|
|
AU2003255845A1
(en)
|
2002-08-22 |
2004-03-11 |
Piramed Limited |
Phosphadidylinositol 3,5-biphosphate inhibitors as anti-viral agents
|
|
EP1591446B1
(en)
|
2003-01-29 |
2013-03-06 |
Takeda Pharmaceutical Company Limited |
Thienopyrimidine compounds and use thereof
|
|
CA2561617A1
(en)
*
|
2004-04-05 |
2005-10-20 |
Aton Pharma, Inc. |
Histone deacetylase inhibitor prodrugs
|
|
JP5213229B2
(ja)
|
2004-04-23 |
2013-06-19 |
エグゼリクシス， インコーポレイテッド |
キナーゼ調節因子および使用方法
|
|
JP4862654B2
(ja)
|
2004-10-08 |
2012-01-25 |
アステラス製薬株式会社 |
芳香環縮合ピリミジン誘導体
|
|
GB0423653D0
(en)
|
2004-10-25 |
2004-11-24 |
Piramed Ltd |
Pharmaceutical compounds
|
|
EP2522397A1
(en)
|
2005-02-03 |
2012-11-14 |
TopoTarget UK Limited |
Combination therapies using HDAC inhibitors
|
|
DK1885710T3
(en)
|
2005-05-18 |
2015-11-23 |
Janssen Pharmaceutica Nv |
SUBSTITUTED AMINOPROPENYLPIPERIDINE OR MORPHOLINE DERIVATIVES AS UNKNOWN INHIBITORS OF HISTONDEACETYLASE
|
|
CA2630717C
(en)
|
2006-01-19 |
2015-02-24 |
Janssen Pharmaceutica N.V. |
Pyridine and pyrimidine derivatives as inhibitors of histone deacetylase
|
|
CN101370791B
(zh)
|
2006-01-19 |
2012-05-02 |
詹森药业有限公司 |
作为组蛋白脱乙酰基酶抑制剂的吡啶和嘧啶衍生物
|
|
EP1981871B1
(en)
|
2006-01-19 |
2011-12-28 |
Janssen Pharmaceutica N.V. |
Heterocyclylalkyl derivatives as novel inhibitors of histone deacetylase
|
|
EP2046799B1
(en)
|
2006-04-26 |
2017-07-19 |
Genentech, Inc. |
Phosphoinositide 3-kinase inhibitor compounds and pharmaceutical compositions containing them
|
|
NZ572812A
(en)
|
2006-04-26 |
2010-09-30 |
Hoffmann La Roche |
THIENO [3, 2-D] PYRIMIDINE Indazole DERIVATIVE USEFUL AS PI3K INHIBITOR
|
|
CL2007001167A1
(es)
|
2006-04-26 |
2008-01-25 |
Genentech Inc |
Compuestos derivados de pirimidina condensada, inhibidores de p13-quinasa; procesos para preparar los compuestos; composicion farmaceutica que los comprende; uso de los compuestos en la preparacion de medicamentos; proceso para preparar la composicion farmaceutica; y kit que incluye a la composicionfarmaceutica.
|
|
EP2018366A4
(en)
|
2006-05-16 |
2010-08-04 |
Univ Mcgill |
HYBRID MOLECULES WITH MIXED VITAMIN D RECEPTOR AGONISM AND HISTONDEACETYLASE RESISTANT PROPERTIES
|
|
KR101434164B1
(ko)
|
2006-09-11 |
2014-08-26 |
쿠리스 인코퍼레이션 |
아연 결합 부분을 함유한 퀴나졸린 계열 ｅｇｆｒ 억제제
|
|
CA2663147A1
(en)
|
2006-09-11 |
2008-03-20 |
Curis, Inc. |
Substituted 2-indolinone as ptk inhibitors containing a zinc binding moiety
|
|
AU2007296743B2
(en)
|
2006-09-11 |
2012-02-16 |
Curis, Inc. |
Tyrosine kinase inhibitors containing a zinc binding moiety
|
|
US20080221132A1
(en)
|
2006-09-11 |
2008-09-11 |
Xiong Cai |
Multi-Functional Small Molecules as Anti-Proliferative Agents
|
|
US20080161320A1
(en)
|
2006-09-11 |
2008-07-03 |
Xiong Cai |
Fused bicyclic pyrimidines as ptk inhibitors containing a zinc binding moiety
|
|
US7547781B2
(en)
|
2006-09-11 |
2009-06-16 |
Curis, Inc. |
Quinazoline based EGFR inhibitors containing a zinc binding moiety
|
|
CN101573333B
(zh)
|
2006-10-28 |
2013-06-12 |
梅特希尔基因公司 |
组蛋白脱乙酰酶抑制剂
|
|
WO2008073785A2
(en)
|
2006-12-07 |
2008-06-19 |
Genentech, Inc. |
Phosphoinositide 3-kinase inhibitor compounds and methods of use
|
|
JP5284977B2
(ja)
|
2006-12-07 |
2013-09-11 |
エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト |
ホスホイノシチド３−キナーゼ阻害剤化合物及び使用方法
|
|
EP2120900A2
(en)
|
2007-02-15 |
2009-11-25 |
Novartis AG |
Combination of lbh589 with other therapeutic agents for treating cancer
|
|
US20080234332A1
(en)
|
2007-03-20 |
2008-09-25 |
Xiong Cai |
Raf kinase inhibitors containing a zinc binding moiety
|
|
WO2009036057A1
(en)
|
2007-09-10 |
2009-03-19 |
Curis, Inc. |
Antiproliferative agents containing a zinc binding moiety
|
|
TW200922564A
(en)
|
2007-09-10 |
2009-06-01 |
Curis Inc |
CDK inhibitors containing a zinc binding moiety
|
|
TW200922590A
(en)
|
2007-09-10 |
2009-06-01 |
Curis Inc |
VEGFR inhibitors containing a zinc binding moiety
|
|
WO2009036020A1
(en)
|
2007-09-10 |
2009-03-19 |
Curis, Inc. |
Mek inhibitors containing a zinc binding moiety
|
|
WO2009036066A1
(en)
|
2007-09-10 |
2009-03-19 |
Curis, Inc. |
Vegfr inhibitors containing a zinc binding moiety
|
|
PE20090678A1
(es)
|
2007-09-12 |
2009-06-27 |
Genentech Inc |
Combinaciones de compuestos inhibidores de fosfoinositida 3-quinasa y agentes quimioterapeuticos y los metodos de uso
|
|
WO2009042646A1
(en)
|
2007-09-24 |
2009-04-02 |
Curis, Inc. |
Anti-proliferative agents
|
|
WO2009055730A1
(en)
|
2007-10-25 |
2009-04-30 |
Genentech, Inc. |
Process for making thienopyrimidine compounds
|
|
US20090149511A1
(en)
|
2007-10-30 |
2009-06-11 |
Syndax Pharmaceuticals, Inc. |
Administration of an Inhibitor of HDAC and an mTOR Inhibitor
|
|
WO2009086012A1
(en)
|
2007-12-20 |
2009-07-09 |
Curis, Inc. |
Aurora inhibitors containing a zinc binding moiety
|
|
EP2311842A3
(en)
|
2008-06-24 |
2011-07-13 |
Takeda Pharmaceutical Company Limited |
PI3K/M TOR inhibitors
|
|
WO2009155659A1
(en)
|
2008-06-27 |
2009-12-30 |
The University Of Queensland |
Combination therapy
|
|
US8196911B2
(en)
|
2008-10-27 |
2012-06-12 |
Honda Motor Co., Ltd. |
Adjustable rate subframe mount
|
|
EP2385832B1
(en)
*
|
2009-01-08 |
2015-07-15 |
Curis, Inc. |
Phosphoinositide 3-kinase inhibitors with a zinc binding moiety
|
|
WO2010089411A2
(en)
|
2009-02-09 |
2010-08-12 |
Universite De La Mediterranee |
Pd-1 antibodies and pd-l1 antibodies and uses thereof
|
|
MX2011009167A
(es)
|
2009-03-12 |
2011-09-15 |
Genentech Inc |
Combinaciones de compuestos inhibidores de fosfoinositida 3-cinasa y agentes quimioterapeuticos para el tratamiento contra neoplasia hemotopoyeticas malignas.
|
|
PE20121816A1
(es)
|
2009-10-12 |
2013-01-02 |
Hoffmann La Roche |
Combinaciones de un inhibidor de pi3k y un inhibidor de mek
|
|
JP2013525308A
(ja)
|
2010-04-16 |
2013-06-20 |
キュリス，インコーポレイテッド |
Ｋ−ｒａｓ変異を有する癌の治療
|
|
PT3111938T
(pt)
*
|
2011-04-01 |
2019-07-10 |
Curis Inc |
Inibidores de fosfoinoritide 3-quinase com uma fração de ligação ao zinco
|
|
US20130102595A1
(en)
|
2011-04-15 |
2013-04-25 |
Curis, Inc. |
Treatment of cancers having k-ras mutations
|
|
TWI835048B
(zh)
|
2011-08-01 |
2024-03-11 |
美商建南德克公司 |
利用pd-1軸結合拮抗劑及mek抑制劑治療癌症之方法
|
|
AU2016281622C1
(en)
|
2015-06-25 |
2021-11-18 |
Immunomedics, Inc. |
Combining anti-HLA-DR or anti-Trop-2 antibodies with microtubule inhibitors, PARP inhibitors, Bruton kinase inhibitors or phosphoinositide 3-kinase inhibitors significantly improves therapeutic outcome in cancer
|
|
CA3040727A1
(en)
*
|
2016-11-02 |
2018-05-11 |
Curis, Inc. |
Combination therapy with a phosphoinositide 3-kinase inhibitor with a zinc binding moiety
|